Startups

CuraSen Therapeutics

CuraSen Therapeutics is a clinical-stage biotechnology company developing oral small-molecule medicines for neurodegenerative and psychiatric diseases. It targets adrenergic receptors to compensate for declining noradrenergic signalling in the brain. Its investigational pipeline includes CuraAX (CST-3056), an alpha-1A adrenoceptor agonist being studied for neurogenic orthostatic hypotension in Parkinson’s disease and related conditions, and the CuraCN and CuraXN beta-2 adrenoceptor agonist combinations for neurodegenerative disease. The company conducts drug discovery and clinical development from San Carlos, California; its medicines remain investigational.

Founded 2018

Team

Anthony FordCo-founder, President, Chief Scientific Officer and Board Director

Gabriel VargasChief Medical Officer

Kathleen Sereda GlaubCo-founder, Chief Executive Officer and Board Director

Loretta TseBoard Director

Mehrdad ShamlooCo-founder and Scientific Advisory Board Chair

Michael P. DillonChief Technical Officer

Patrick EnrightBoard Chair

Peter ButeraSenior Vice President, Operations

Renee MartinVice President, Translational Science

Robert BoothCo-founder, Distinguished Advisor and Scientific Advisory Board Member

Ronald HuntBoard Director

Simon TateBoard Director

Investments

$—2023-10-09	Alzheimer's Drug Discovery Foundation
$54M2018-10-17	New Leaf Venture Partners, Longitude Capital, Tekla Capital Management, Alta Partners, Johnson & Johnson Innovation – JJDC, Pappas Capital
$—Unknown date	Chiesi Ventures

team@apexlogos.ai3 hours ago
Primary company about/leadership/pipeline and October17,2018 SeriesA announcement: https://www.curasen.com/curasen-therapeutics-announces-54-5-million-series-a-financing-with-industry-veterans-at-helm-to-develop-drugs-targeting-novel-mechanism-for-the-treatment-of-neurodegenerative-diseases/ . A is USD54.5m with six explicitly named investor groups; body October17 overrides news-indexOctober14. October9,2023 ADDF strategic investment is up to USD5.8m, a cap rather than an exact received amount, recorded NULL. Chiesi ownportfolio https://www.chiesiventures.com/portfolio-companies/ confirms an undated relationship; it is not substituted for PappasCapital in the 2018 A. Company’s current about page also names abrdn funds and ICG, but exact investing adviser/fund and financing dates still need verification. Tekla2018 participation is retained as historicalmanager, not automatically transferred to abrdnInc. KathleenSeredaGlaub currentCEO supersedes oldAnthonyFordCEO; Ford is PresidentCSO. Twelve unique current leadership/adviser/board people saved; outsidefirmjobs are not company executive titles.